"Designing Growth Strategies is in our DNA"
Fibroblast Growth Factor Receptor 4 (FGFR4) is a tyrosine kinase receptor present on the cell surface and encoded by the FGF genes. Fibroblast growth factor receptor 4 plays a vital role in cell processes such as regulating cell proliferation, migration, differentiation, bile acid biosynthesis, and metabolism. The members of the FGFR family differ in their tissue distribution and ligand specificity. Hence, the activation of FGFR4 is highly associated with amplification of FGF19, a ligand specific for FGFR4.
In the case of hematologic malignancies and solid tumors, the FGFR4 acts as an oncogene driving factor due to an increased level of FGF19 specific ligand. FGFR4 inhibitors are emerging as a potential therapeutic agent for the treatment of various types of cancer. Targeting FGFR4 through small-molecule inhibitors can be more feasible and can be developed using structure-guided drug design.
FGFR4 Inhibitors are attracting huge pharmaceutical and research focus on the development of novel targeted therapy against cancer. Furthermore, the rising prevalence of cancer is also one of the major factors in encouraging pharmaceutical companies to develop novel drugs. For instance; Novartis AG has initiated phase 1 study on FGF401 for the treatment of patients with hepatocellular carcinoma.
To know how our report can help streamline your business, Speak to Analyst
At present, around 60% of the pipeline candidates for Fibroblast Growth Factor Receptor 4 (FGFR4) are in the phase-1 stage. Majority of the studies have been sponsored by pharmaceutical companies.
The report on ‘Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors.
The report on ‘Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.